• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.

作者信息

Braslis K G, Davi R C, Nelson E, Civantos F, Soloway M S

机构信息

Department of Urology and Pathology, University of Miami School of Medicine, Florida.

出版信息

Urology. 1995 Feb;45(2):329-31. doi: 10.1016/0090-4295(95)80028-x.

DOI:10.1016/0090-4295(95)80028-x
PMID:7855985
Abstract

We report a primary squamous cell carcinoma of the prostate that developed in a 57-year-old man, 3 years after treatment with leuprolide and flutamide for Stage D1 adenocarcinoma of the prostate. This is the first case that describes this transformation from adenocarcinoma to squamous cell carcinoma following the use of luteinizing hormone agonists.

摘要

相似文献

1
Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
Urology. 1995 Feb;45(2):329-31. doi: 10.1016/0090-4295(95)80028-x.
2
Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.前列腺癌治疗后类似卵巢黏液瘤样改变：新辅助雄激素消融治疗患者的一种独特模式
Am J Surg Pathol. 1998 Mar;22(3):347-54. doi: 10.1097/00000478-199803000-00010.
3
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.比卡鲁胺与氟他胺分别联合促黄体生成素释放激素类似物治疗晚期前列腺癌的对照试验。康士得联合研究组。
Urology. 1995 May;45(5):745-52. doi: 10.1016/s0090-4295(99)80077-6.
4
The use of flutamide in hormone-refractory metastatic prostate cancer.
Cancer. 1993 Dec 15;72(12 Suppl):3870-3. doi: 10.1002/1097-0142(19931215)72:12+<3870::aid-cncr2820721721>3.0.co;2-e.
5
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.比卡鲁胺与氟他胺分别联合促黄体生成素释放激素类似物治疗晚期前列腺癌的对照试验。进展时间分析。康士得联合研究组。
Cancer. 1996 Nov 15;78(10):2164-9. doi: 10.1002/(sici)1097-0142(19961115)78:10<2164::aid-cncr18>3.0.co;2-x.
6
[Endometrioid adenocarcinoma of the prostate. Apropos of a case, review of the literature].
J Urol (Paris). 1992;98(2):108-11.
7
Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.精囊局限性淀粉样变性。可能与激素治疗的前列腺腺癌有关。
Arch Pathol Lab Med. 1997 Dec;121(12):1265-8.
8
[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
J Urol (Paris). 1996;102(3):123-5.
9
Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.前列腺癌雄激素剥夺治疗的病理学。173例患者的比较研究。
Cancer. 1995 Apr 1;75(7):1634-41. doi: 10.1002/1097-0142(19950401)75:7<1634::aid-cncr2820750713>3.0.co;2-#.
10
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.联合内分泌治疗（促黄体生成素释放激素激动剂与氟他胺）对正常前列腺及前列腺腺癌的影响：一项组织病理学与免疫组织化学研究
Am J Surg Pathol. 1991 Feb;15(2):111-20. doi: 10.1097/00000478-199102000-00002.

引用本文的文献

1
Epigenetic regulation of p63 blocks squamous-to-neuroendocrine transdifferentiation in esophageal development and malignancy.表观遗传调控 p63 阻止食管发育和恶性肿瘤中的鳞状细胞向神经内分泌转化。
Sci Adv. 2024 Oct 11;10(41):eadq0479. doi: 10.1126/sciadv.adq0479. Epub 2024 Oct 9.
2
Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis.前列腺混合性腺鳞状细胞癌，原发灶和肝转移灶均行配对测序。
Curr Oncol. 2024 Apr 24;31(5):2393-2399. doi: 10.3390/curroncol31050178.
3
Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.
促黄体生成素释放激素（LHRH）激动剂和放疗治疗后前列腺腺癌向鳞状细胞癌的转化。
Pan Afr Med J. 2019 Nov 1;34:125. doi: 10.11604/pamj.2019.34.125.19421. eCollection 2019.
4
Transformation of adenocarcinoma of prostate to squamous cell carcinoma following hormonal treatment: A case report and review of the literature.激素治疗后前列腺腺癌转化为鳞状细胞癌：一例报告并文献复习
Radiol Case Rep. 2019 Feb 11;14(4):483-489. doi: 10.1016/j.radcr.2019.01.015. eCollection 2019 Apr.
5
Squamous cell carcinoma of the prostate following treatment with an LHRH-agonist: a rare case of transformation of adenocarcinoma of the prostate.促性腺激素释放激素（LHRH）激动剂治疗后发生的前列腺鳞状细胞癌：1例罕见的前列腺腺癌转化病例。
Cent European J Urol. 2014;67(1):26-8. doi: 10.5173/ceju.2014.01.art5. Epub 2014 Apr 17.
6
Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature.前列腺癌中鳞状分化的诊断难题：病例报告及文献复习。
Diagn Pathol. 2011 May 31;6:46. doi: 10.1186/1746-1596-6-46.
7
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation.前列腺鳞状细胞癌：联合化疗-放疗后的长期生存。
Radiat Oncol. 2007 Apr 3;2:15. doi: 10.1186/1748-717X-2-15.